Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer

Study phase: II

Study phase (if other): III

Primary disease category: Cancer

Secondary disease categories: Cancer, Lung Cancer

Sponsor: Southwest Oncology Group

Protocol number: S1400

Projected enrollment dates: June 2015 to April 2022

Official study title: S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer